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highly signiﬁcant (-1.766, 95% CI: -1.073 to -2.458, p=0.000,
n=112; and -2.320, CI: -3.838 to -0.803, p=0.011, n=41) The ob-
served success rates for the pain subscale reached 37% by two
months and 31.7% by six months. Two months after treatment
initiation, WOMAC physical function subscale scores and global
assessment decreased signiﬁcantly (-4.772, 95% CI: -6.864 to
-2.681, p=0.000; -7.105, 95% CI: -9.936 to -4.274, p=0.013). The
changes at six months were not statistically signiﬁcant (n=41 pa-
tients). The success rates for the physical function subscale and
global WOMAC index were 31.4% and 34.5% by two months
(n=112) and 31.7% and 34.1% by six months (n=41).
The PRGF treatment performed as described above resulted
in a moderate enrichment in platelet number; a 2.0 ± 0.5-fold
increase compared to peripheral blood. The levels of the main
platelet secretory growth factors were 27.28 ± 10.90 ng/cc for
TGF-β1 and 15.66 ± 8.02 ng/cc for PDGF. VEGF was also se-
creted from platelets but was less abundant. Other GFs present
in PRGF reﬂect mainly plasma levels; among these growth fac-
tors are IGF-I (55.53 ± 20.87 ng/cc) and the less concentrated
HGF (472 ± 221 pg/cc).
Conclusions: Continued research on autologous therapies
might yield a new therapeutic option for OA treatment in se-
lected patients
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Purpose: Previous studies have shown that Non-Steroidal Anti-
Inﬂammatory Drugs (NSAIDs) may inhibit the antihypertensive
effect of Angiotensin Converting Enzyme Inhibitors (ACEIs). We
studied whether lumiracoxib 100 mg od would have less impact
on 24-hour mean ambulatory blood pressure (MABP) compared
to ibuprofen 600 mg tid in osteoarthritis (OA) patients with con-
trolled hypertension treated with ACEI monotherapy.
Methods: This was a 4-week, multicenter, randomized, double-
blind, double-dummy, parallel group study of hypertensive OA
patients aged ≥50 years (ofﬁce blood pressure (BP) <140/90
mmHg) on stable antihypertensive treatment. All subjects were
randomized to take either lumiracoxib 100 mg od or ibuprofen 600
mg tid (1:1). The main outcome measure was the change from
baseline in 24-hour systolic MABP at 4 weeks. Other measures
included change from baseline in 24-hour diastolic MABP as well
as daytime and night-time systolic and diastolic MABP. Here,
we report a post-hoc subgroup analysis of subjects taking ACEI
monotherapy for hypertension.
Results: Of the 787 patients randomized in the study, 82 were
taking ACEI monotherapy. 42 were randomized to lumiracoxib
and 40 to ibuprofen. The change from baseline (least square [LS]
means) in 24-hour systolic MABP was -4.6 mmHg for lumiracoxib
and +3.7 mmHg with ibuprofen at 4 weeks, estimated treatment
difference -8.2 mmHg [95% CI -12.1,-4.4], p<0.001. The change
from baseline (LS means) in 24-hour diastolic MABP was - 2.0
mmHg for lumiracoxib and +2.0 mmHg for ibuprofen at 4 weeks,
estimated treatment difference -4.0 mmHg [95% CI -6.6, -1.4],
p=0.003). This compared with a difference in 24-hour systolic
MABP of -5.0 mmHg [95% CI -6.1,-3.8], p<0.001) and diastolic
MABP of -2.0 mmHg [95% CI -2.7,-1.3], p<0.001) in the overall
patient population. For the LS mean change from baseline in
daytime and night-time systolic MABP, the estimated treatment
differences were -9.4 mmHg [95% CI -13.9,-4.9], p<0.001 and
-5.4 mmHg [95% CI -9.4,-1.4], p=0.008. Similar results were
obtained for the LS mean change from baseline in daytime and
night-time diastolic MABP, with estimated treatment differences
of -4.3 mmHg [95% CI -7.4,-1.1], p=0.009 and -2.8 mmHg [95%
CI -5.7,-0.0], p=0.049.
Conclusions: Lumiracoxib 100 mg od resulted in less destabi-
lization of BP compared with ibuprofen 600 mg tid in controlled
hypertensive OA patients treated with ACEI monotherapy. Ac-
cording to this post-hoc analysis, treatment differences may be
more pronounced in patients using ACEI monotherapy. Whilst
these ﬁndings are not deﬁnitive, they point to important dif-
ferences in the effect of different NSAIDs on BP control in
hypertensive osteoarthritis patients who are taking ACEIs.
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Purpose: Unicompartmental arthroplasty may provide better al-
ternative for physiological function, quicker recovery and long-
term satisfaction compared to TKA and repeat arthroscopic inter-
ventions. The purpose of this study was to prospectively evaluate
outcomes following unicompartmental knee arthroplasty as well
as predictors for patient satisfaction.
Methods: 62 consecutive patients were prospectively studied
(45 medial replacements, 17 lateral replacements)] underwent
unicompartmental arthroplasty from 2000-2005. There were 34
males and 49 females [average age of 69.87 (range 40-92)].
Eighty-six percent had at least 2 year follow-up. Assessment
included preoperative and postoperative range of motion, sub-
jective questionnaire, KT-1000, plain radiograph knee series in-
cluding 3-foot alignment ﬁlms. A 1.5-Tesla MRI was completed in
all patients but one who had a pacemaker.
Results: All patients reported severe knee pain preoperatively
involving one compartment. One patient died. Two patients were
converted to a total knee arthroplasty (medial replacements).
Average follow-up was 33 months (range: 24-56 months). The
average post-surgical Lysholm score was 91 (range 62 to 100),
with a preoperative Lysholm of 57 (range 31 to 92) (p=0.001).
The Tegner activity score improved from 2.8 (1 to 7) preopera-
tively to 4(1 to 8) postoperative(p=0.001). The preoperative HSS
score improved from 67(45 to 87) to 92 (77 to 100)(p=0.001). For
patients who underwent medial replacements, they had lower
preoperative Lysholm (42 vs. 57) if they had grade 3 or 4 degen-
erative changes, as read on the MRI, in the lateral compartment;
however, there was not difference in post-op Lysholm (89 vs
92;p=0.419). This was also seen in patients with grade 3 or 4
degenerative changes in the medial compartment that underwent
lateral replacement. Age was correlated with post-operative Teg-
ner scores(r=-0.586, p=0.001). Independent predictor of patient
satisfaction was postoperative Tegner score (r2=0.26; p=0.04).
Conclusions: Determining speciﬁc patient selection criteria im-
proves patient outcomes and helps with patient education. This
study demonstrates that patients can return to high level of func-
tion and activity following unicompartmental arthroplasty. The
presence of degenerative changes seen on MRI on the opposite
compartment does not correlate to decreased function or activity.
Patient satisfaction is high and it related to activity level, which
this type of arthroplasty allows for more high level activities.
